---
title: "阿斯利康在京啓用全球戰略研發中心"
description: "從阿斯利康獲悉，其在京正式啓用全新全球戰略研發中心。該研發中心為阿斯利康全球第六個、在華第二個戰略研發中心，也是阿斯利康 25 億美元在華投資計劃的核心項目。據悉，全球研發北京戰略中心擁有人工智能和數據科學中心，旨在加速藥物早期研究成果向臨牀開發轉化。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/262725487.md"
published_at: "2025-10-25T09:47:52.000Z"
---

# 阿斯利康在京啓用全球戰略研發中心

> 從阿斯利康獲悉，其在京正式啓用全新全球戰略研發中心。該研發中心為阿斯利康全球第六個、在華第二個戰略研發中心，也是阿斯利康 25 億美元在華投資計劃的核心項目。據悉，全球研發北京戰略中心擁有人工智能和數據科學中心，旨在加速藥物早期研究成果向臨牀開發轉化。

從阿斯利康獲悉，其在京正式啓用全新全球戰略研發中心。該研發中心為阿斯利康全球第六個、在華第二個戰略研發中心，也是阿斯利康 25 億美元在華投資計劃的核心項目。據悉，全球研發北京戰略中心擁有人工智能和數據科學中心，旨在加速藥物早期研究成果向臨牀開發轉化。

### Related Stocks

- [AZN.US - 阿斯利康](https://longbridge.com/zh-HK/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Deutsche Bank  Keeps Their Sell Rating on AstraZeneca (AZN) | Deutsche Bank analyst Emmanuel Papadakis has maintained a Sell rating on AstraZeneca (AZN) with a price target of £115.0 | [Link](https://longbridge.com/zh-HK/news/276058097.md) |
| SLE and LN market expected to reach $5.9bn across 7MM by 2034 | A significant growth in the systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the seven major ma | [Link](https://longbridge.com/zh-HK/news/276212995.md) |
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/zh-HK/news/276017486.md) |
| 11:23 ETAI in Biotechnology Market Size to Reach USD 1,971 Million by 2031 \| Valuates Reports | The global AI in Biotechnology market is projected to grow from USD 1,033 million in 2024 to USD 1,971 million by 2031,  | [Link](https://longbridge.com/zh-HK/news/276147064.md) |
| Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins | Nuclera and leadXpro have announced a partnership to enhance structure-based drug design for complex membrane proteins.  | [Link](https://longbridge.com/zh-HK/news/276109364.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。